# DYN catalysts: Dyne Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dyn/catalysts

> Dyne Therapeutics, Inc. (DYN) has 8 upcoming catalysts. The next is the basivarsen topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for DYN?

Dyne Therapeutics, Inc. (DYN) has 8 upcoming catalysts. The next is the basivarsen topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -" [Calendar and source filings](https://sec-api.dev/companies/dyn/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-254597, https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-06-03. Cite: https://sec-api.dev/companies/dyn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Dyne Therapeutics, Inc. |
| Ticker | DYN (Nasdaq) |
| SEC CIK | 1818794 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/dyn |

## Cash runway

Cash $1.13B as of 2026-09-30; quarterly burn $177.5M; about 19.2 months of runway at that rate (XBRL company facts, accession 0001818794-26-000012).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [Extension topline data readout](https://sec-api.dev/pdufa/extension) | DYN |  | completed, positive | "In September 2024, we announced the completion of the MAD portion of the trial, and in December 2025, we announced positive topline data from the REC portion of the trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818794/000119312526084178/dyn-20251231.htm)) |
| November 12, 2024 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/dyn-ex99_1.htm)) |
| 2025 | [Satralizumab trial start](https://sec-api.dev/pdufa/satralizumab) | DYN | FSHD and plans to initiate a global Phase 1/2 clinical trial in 2025 | scheduled | "Additionally, satralizumab, an anti-IL-6 antibody, is being evaluated in a Phase 1 clinical trial by the University Hospital of Nice and clenbuterol, a beta (2) agonist, is being evaluated in a Phase 2 clinical trial by Springbok Analytics, Inc. Epicrispr Biotechnologies, Inc. recently announced that the FDA has cleared an IND application for EPI-321, an epigenetic therapy for the treatment of FSHD and plans to initiate a global Phase 1/2 clinical trial in 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818794/000119312525266882/dyn-20250930.htm)) |
| February 27, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/dyn-ex99_1.htm)) |
| mid-2025 | [Z-basivarsen trial start](https://sec-api.dev/pdufa/z-basivarsen) | DYN |  | scheduled | "Dyne continues to pursue Accelerated Approval in the U.S. based on splicing as a surrogate endpoint and plans to initiate a global placebo-controlled Registrational Expansion Cohort in the ACHIEVE trial that will include up to 48 patients with full enrollment planned for mid-2025 and data from this cohort planned for H1 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/dyn-ex99_1.htm)) |
| May 8, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/dyn-ex99_1.htm)) |
| July 15, 2025 | [Dyne Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818794/000095017025099161/dyn-20250630.htm)) |
| July 28, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/dyn-ex99_1.htm)) |
| November 5, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525266979/dyn-ex99_1.htm)) |
| December 8, 2025 | [Rostudirsen topline data readout](https://sec-api.dev/pdufa/rostudirsen) | DYN | Duchenne muscular dystrophy | completed, positive | "WALTHAM, Mass., December 8, 2025 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced positive topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518dex991.htm)) |
| Mar 2026 | [Z-basivarsen trial start](https://sec-api.dev/pdufa/z-basivarsen) | DYN |  | completed | "Dyne remains on track to initiate a global confirmatory Phase 3 clinical trial of z-basivarsen in March 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-ex99_1.htm)) |
| March 2, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-ex99_1.htm)) |
| Q2 2026 | [Z-rostudirsen trial start](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | scheduled | "Dyne plans to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm)) |
| Q2 2026 | [Z-rostudirsen NDA/BLA submission](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | scheduled | "- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm)) |
| Q2 2026 | [Rostudirsen NDA/BLA submission](https://sec-api.dev/pdufa/rostudirsen) | DYN |  | scheduled | "The Company plans to submit a Biologics License Application ("BLA") for U.S. Accelerated Approval in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518d8k.htm)) |
| May 2026 | [Z-rostudirsen trial start](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | completed | "Dyne initiated the global confirmatory Phase 3 FORZETTO trial of z-rostudirsen in May 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm)) |
| May 11, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm)) |
| Jul 2026 | [Z-rostudirsen NDA/BLA acceptance](https://sec-api.dev/pdufa/z-rostudirsen) | DYN | individuals with DMD amenable to exon 51 skipping | completed | "In July 2026, we announced that the FDA accepted for review our BLA for z-rostudirsen for the treatment of individuals with DMD amenable to exon 51 skipping." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000012/dyn-20260930.htm)) |
| July 20, 2026 | [Rostudirsen NDA/BLA acceptance](https://sec-api.dev/pdufa/rostudirsen) | DYN | individuals with Duchenne muscular dystrophy | completed | "On July 20, 2026, Dyne Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its biologics license application ("BLA") for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy ("DMD") amenable to exon 51 skipping." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/dyn-20260720.htm)) |
| July 29, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm)) |
| November 5, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm)) |
| Q1 2027 | [Basivarsen topline data readout](https://sec-api.dev/pdufa/basivarsen) | DYN |  | scheduled | "- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-ex99_1.htm)) |
| Q1 2027 | [Z-basivarsen topline data readout](https://sec-api.dev/pdufa/z-basivarsen) | DYN |  | scheduled | "- Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm)) |
| Q1 2027 | [Z-rostudirsen topline data readout](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | scheduled | ""This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm)) |
| Q1 2027 | [Dyne Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | scheduled | "The change from baseline in vHOT at 6 months is the primary endpoint of the ACHIEVE REC, from which topline data are expected in the first quarter of 2027 to support a potential Biologics License Application ("BLA") submission for U.S. Accelerated Approval in the third quarter of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000009/dyn-20260929.htm)) |
| January 21, 2027 | [Z-rostudirsen PDUFA date](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | scheduled | "- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm)) |
| Q3 2027 | [Z-basivarsen NDA/BLA submission](https://sec-api.dev/pdufa/z-basivarsen) | DYN |  | scheduled | "- Reaffirming expected cash runway into Q3 2027, beyond Dyne's first planned commercial launch of z-rostudirsen in DMD and potential z-basivarsen BLA submission in DM1 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525266979/dyn-ex99_1.htm)) |
| July 2028 | [Zeleciment basivarsen (dyne-101) primary completion](https://sec-api.dev/pdufa/zeleciment-basivarsen-dyne-101) | DYN | Myotonic Dystrophy Type 1 (DM1); DM1; Myotonic Dystrophy | scheduled | "NCT07486934 (Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Dyne Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486934)) |
| Jul to Oct 2028 | [Zeleciment basivarsen (dyne-101) topline data readout](https://sec-api.dev/pdufa/zeleciment-basivarsen-dyne-101) | DYN | Myotonic Dystrophy Type 1 (DM1); DM1; Myotonic Dystrophy | scheduled | "NCT07486934 (Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Dyne Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486934)) |

## Drugs

- [Basivarsen](https://sec-api.dev/pdufa/basivarsen): 
- [Rostudirsen](https://sec-api.dev/pdufa/rostudirsen): individuals with duchenne muscular dystrophy, duchenne muscular dystrophy
- [Satralizumab](https://sec-api.dev/pdufa/satralizumab): fshd and plans to initiate a global phase 1/2 clinical trial in 2025
- [Z-basivarsen](https://sec-api.dev/pdufa/z-basivarsen): 
- [Z-rostudirsen](https://sec-api.dev/pdufa/z-rostudirsen): individuals with dmd amenable to exon 51 skipping
- [Zeleciment basivarsen (dyne-101)](https://sec-api.dev/pdufa/zeleciment-basivarsen-dyne-101): Myotonic Dystrophy Type 1 (DM1)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dyn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DYN catalysts: Dyne Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dyn/catalysts

```bibtex
@misc{secapidev_companies_dyn_catalysts_20261116,
  title        = {DYN catalysts: Dyne Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dyn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dyn_catalysts_20261116","title":"DYN catalysts: Dyne Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dyn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
